Safety warning for chadox1 ncov-19 vaccine in patients with sickle cell disease

S. Alkindi*, R. A. Elsadek, A. V. Pathare

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Vaccines against acute respiratory syndrome Coronavirus 2(SARS-CoV2) are critical weapons to control the spread of the deadly Coronavirus 2019(COVId-19) virus worldwide. Although these vaccines are generally safe, their widespread use has produced reports of rare complications, including vaccine-induced immune thrombotic thrombocytopenia (VIITT), particularly in connection with ChAdOx1 nCov-19. We have identified three cases of sickle cell disease (SCD) experiencing a severe vaso-occlusive crisis (VOC) shortly after the vaccine. Despite being stable for a long time, they had fever with tachycardia, along with a significant rise in WBC, liver enzymes, particularly alkaline phosphate, with a remarkable drop in hemoglobin, and platelets and one of them had probably a fatal TTP like syndrome. Given these findings, physicians and patients should exercise caution when taking this type of vaccine and be aware of these safety concerns.

Original languageEnglish
Article numbere2021059
JournalMediterranean Journal of Hematology and Infectious Diseases
Issue number1
Publication statusPublished - 2021
Externally publishedYes


  • ChAdOx1 nCov-19 vaccine
  • SARS-CoV2
  • Sickle cell disease
  • Vaccine-induced immune thrombotic thrombocytopenia
  • Vaso-occlusive crisis

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases


Dive into the research topics of 'Safety warning for chadox1 ncov-19 vaccine in patients with sickle cell disease'. Together they form a unique fingerprint.

Cite this